Compare
West Pharmaceutical Services Inc vs Teleflex Inc vs ResMed Inc vs Embecta Corp.
| Latest fiscal year | West Pharmaceutical Services Inc WST | Teleflex Inc TFX | ResMed Inc RMD | Embecta Corp. EMBC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-09-30 |
| Revenue | $3.07B | $1.99B | $5.65B | $1.08B |
| Revenue growth (YoY) | +6.3% | +17.2% | +9.9% | -3.8% |
| Gross margin | 35.9% | 56.2% | 61.1% | 62.6% |
| Operating margin | 19.0% | 5.9% | 33.4% | 22.4% |
| Net margin | 16.1% | -45.4% | 26.9% | 8.8% |
| Net income | $493.70M | -$905.64M | $1.52B | $95.40M |
| EPS (Diluted) | $6.79 | -$20.25 | $10.43 | $1.62 |
| Operating cash flow | $754.80M | $96.68M | $1.81B | $191.70M |
| Free cash flow | $468.90M | $1.45M | $1.65B | $182.40M |
| Cash & equivalents | $791.30M | $378.56M | $1.47B | $225.50M |
| Total assets | $4.27B | $6.95B | $8.97B | $1.09B |
| Total liabilities | $1.09B | $3.82B | $2.38B | n/a |
| Shareholders' equity | $3.18B | $3.12B | $6.59B | -$650.60M |
| Return on year-end equity | 15.5% | -29.0% | 23.1% | n/a |
| Shares outstanding | 72.00M | n/a | 144.24M | 58.50M |
Revenue, most recent five fiscal years
| Fiscal year | West Pharmaceutical Services Inc | Teleflex Inc | ResMed Inc | Embecta Corp. |
|---|---|---|---|---|
| Latest | $3.07B Ended 2025-12-31 | $1.99B Ended 2025-12-31 | $5.65B Ended 2026-06-30 | $1.08B Ended 2025-09-30 |
| 1 year earlier | $2.89B Ended 2024-12-31 | $1.70B Ended 2024-12-31 | $5.15B Ended 2025-06-30 | $1.12B Ended 2024-09-30 |
| 2 years earlier | $2.95B Ended 2023-12-31 | $1.71B Ended 2023-12-31 | $4.69B Ended 2024-06-30 | $1.12B Ended 2023-09-30 |
| 3 years earlier | $2.89B Ended 2022-12-31 | $2.79B Ended 2022-12-31 | $4.22B Ended 2023-06-30 | $1.13B Ended 2022-09-30 |
| 4 years earlier | $2.83B Ended 2021-12-31 | $2.81B Ended 2021-12-31 | $3.58B Ended 2022-06-30 | $1.17B Ended 2021-09-30 |